Last updated: June 5, 2026

Back to directory

Oxipit ChestLink medical AI product profile

CE Class IIb autonomous chest X-ray AI workflow positioned to identify normal studies and generate reports without radiologist review in selected markets.

Screenshot of the official Oxipit ChestLink product page
Medical imaging and radiology

Best fit

European radiology programs studying tightly governed autonomous normal-study reporting after retrospective and supervised validation.

Primary use case
Autonomous reporting of high-confidence normal chest X-ray studies, chest radiograph triage, and radiologist workload reduction
Audience
Radiology departments, imaging networks, chest X-ray services, and governance teams evaluating autonomous normal-CXR reporting
Risk level
High
Pricing signal
Enterprise radiology pricing; verify current Sectra/Oxipit commercial path, market availability, module scope, and integration terms.
Official sources
5 official sources

Compare within workflow: Medical imaging and radiology · comparison shortlist · source index

Regulatory, privacy, evidence, and workflow lens

Product-specific review. These product-specific signals summarize what the cited sources imply before treating Oxipit ChestLink as safe for a local clinical, operational, or research workflow.

Regulatory / FDATreat ChestLink as a high-risk autonomous radiology workflow and verify the exact CE Class IIb certificate, intended use, country availability, version, and absence or presence of FDA authorization before any clinical deployment.
PrivacyReview DICOM image routing, patient identifiers, RIS/PACS integration, analytics dashboards, support access, retention, security controls, and the customer data-processing agreement rather than relying on the public website privacy notice.
EvidenceRequire local retrospective validation and supervised operation data before autonomous release, with special attention to false negatives, abnormality prevalence, scanner mix, excluded cases, and monitoring sensitivity.
WorkflowBest governed as a staged autonomous-normal-CXR program with explicit release thresholds, radiologist oversight for all uncertain or abnormal cases, audit review, downtime fallback, and safety-event escalation.

Where Oxipit ChestLink fits

Oxipit describes ChestLink as a CE Class IIb autonomous AI imaging application for chest X-ray analysis that reports high-confidence studies with no abnormalities; Oxipit materials outline retrospective, supervised, and autonomous deployment phases, while Sectra announced and completed its acquisition of Oxipit in 2026. Oxipit's privacy notice is a website notice, so clinical data-processing terms should be checked contractually.

Not for: U.S. clinical use without FDA authorization, abnormal-study reporting, unsupported modalities, emergency workups without escalation, or replacing local radiologist accountability outside the certified workflow.

What to verify before using Oxipit ChestLink

Source links

Use these links to confirm current claims, terms, regulatory status, pricing, and deployment requirements.

Related medical AI products